Reuters |
AstraZeneca's patent on asthma drug invalidated by US court
Reuters NEW YORK (Reuters) – A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version. Actavis Plc said that the U.S. District … Actavis launches Pulmicort Respules generic on AZ legal loss |
View full post on asthma – Google News